Pharma Career Starter Map
A self-study map into the pharma industry: Chinese → AI tools → domain → regulations → network, across six career lines (excipients / intermediates / APIs / formulations / licensing / M&A) with skills, study time and income references. Language follows the global switch (ZH / EN / ES / JA / KO / IT).
Pharma Career Starter Map
Five steps: Chinese → AI tools → domain → regulations → network; six career tracks to choose
This page is your entry cockpit. Whether you are a fresh graduate, a career-switching lawyer, or a foreign friend who wants to work in pharma with China — follow this map and you can go from zero to working independently within 12 months. Every stop lists what to learn, which tools to use, how long it takes and how to check yourself. Each of the six career tracks comes with its own growth path, skill list and income reference. The map links straight into our courses: learn, practise, come back and check.
1. The five-step ladder: Chinese → AI tools → domain → regulations → network
There is no fixed order to enter the industry, but there is an order to learning. Language is your entry ticket, AI is your lever, domain knowledge is your living, regulations are your shield, and your network is the amplifier. Each step lists what to learn, what to use, and a self-check — do not move on before you can pass it.
Chinese & jargon (for foreigners) · foreign languages & jargon (for Chinese newcomers)
Time 1–2 months to build the base, then keep adding 20 terms a week- ▸Pharma trade jargon: enquiry, quotation, PI, contract, production, QC, shipping, clearance, collection — the ten-step deal chain
- ▸Product & quality words: CAS numbers, pharmacopoeias (CP/USP/EP/JP), CoA, batch number, expiry, impurities, residual solvents
- ▸Build your own Chinese–English–Spanish glossary (20 terms a week; 500+ in a year — that is a portfolio piece)
- ▸For foreigners: pass HSK 3–4 everyday vocabulary first, then industry terms. For Chinese newcomers: English is the working language; Spanish, French or Russian is your edge
✓ Given an English enquiry, you can explain in Chinese what the customer wants
✓ Seeing a CAS number and a pharmacopoeia abbreviation, you know what they are and where to check them
✓ Your glossary holds 50+ tri-lingual entries you wrote yourself
AI tools: make AI your teammate
Time 2–4 weeks to get going, then lifelong refinement. Master one first — do not pay for ten at once- ▸The foundation trio: ChatGPT (general Q&A/writing, top-tier ES & EN), Claude (long documents, code, complex analysis), Gemini (Google suite integration, generous free tier)
- ▸The four-step delegation formula: what to do + what you have + what you want + plan first, execute later (confirming a plan is 100× cheaper than rework)
- ▸Three modes: Plan (plan first, then execute — the safe default for beginners), Craft (get straight to work), Ask (questions only, no changes)
- ▸Pick output tools by goal: Canva (posters/decks), Gamma (client-ready decks in seconds), Notion AI (knowledge management), Zapier/n8n (automation)
- ▸The floor for using AI: ask well, verify answers, and know when not to trust it (numbers and compliance documents must be human-checked)
✓ You can turn a vague request into a 'what to do + what you have + what you want' prompt and make AI plan before acting
✓ On an AI-drafted quotation you can spot at least one number that needs human verification
✓ You have run one full workflow: raw material → AI processing → finished output → your own acceptance check
Domain knowledge: products, process and the numbers
Time 2–3 months (1.5 hours a day + one hands-on exercise a week)- ▸The four product lines: excipients / intermediates / APIs / formulations — different uses, margins, barriers and payment terms (see the six tracks below)
- ▸Pharmacopoeias: how CP (China), USP (US), EP (Europe) and JP (Japan) differ and which market each serves
- ▸The trade chain: Inquiry → Quotation → PI → Contract → Production → QC → Shipping → Clearance → Payment
- ▸Quotation & costing: cost build-up, FX, freight, margin, tiered pricing; the two lines you never cross and the zero-rebate trap
- ▸Terms & payment: FOB/CIF/EXW/DDP (Incoterms 2020), T/T, L/C, and the risk comparison of open-account terms
✓ You can walk one deal from enquiry to cash collection, saying who does what and where each document lives
✓ Given a product, you can classify it, name the applicable pharmacopoeia and suggest a price
✓ You survive six quarters in the simulation without a loss-making deal (your score never zeroes out)
Regulations & compliance: the industry's shield
Time 2–3 months to start, plus lifelong updates (regulations are alive)- ▸The six compliance documents: DMF, CEP/COS, CoA, TDS, SDS, GMP certificates — the entry ticket of pharma trade; learn to spot fakes at a glance
- ▸Registration map: NMPA (China), FDA (US), EMA/EDQM (Europe), LatAm (ANMAT Argentina, INVIMA Colombia, COFEPRIS Mexico)
- ▸EU REACH and the three SVHC lists: registration, notification and communication duties (compulsory for the Europe line)
- ▸Contract core clauses: quality disputes, arbitration seat, force majeure, IP, liability caps — where legally trained people shine
- ▸Red lines: bad debt on credit terms, expired certificates, forged documents, GDPR (no cold emails to the EU-27/UK/Switzerland), and what may be said to customers
✓ Given a CEP copy, you can judge its authenticity, validity and scope
✓ For an EU customer, you can name the three compliance documents you must obtain first
✓ You know the cold-email red line: which countries/regions are strictly off-limits
Network & market: let opportunities find you
Time Start in month 3: reach out to two industry people a week, for life- ▸Trade fairs are the densest networking there is: CPHI China (Shanghai, around June each year), CPHI Worldwide, API China — go at least once a year
- ▸LinkedIn prospecting: formulation plants, importers, distributors. Review reply rates weekly and iterate your pitch every week
- ▸Keep feeding on industry media & databases: PharmaCube, Pharmacodia, Endpoints, Fierce Pharma, Citeline/Cortellis (subscription — verify current terms)
- ▸From meeting people to holding relationships: follow-up rhythm, sole agencies, annual visits — relationships compound
✓ You hold 20 industry contacts you can actually talk to (not just accepted invitations)
✓ You can state your category + region focus in one sentence anyone understands
✓ Your outreach emails get replies — and you know why
2. Six career tracks: pick one and climb
The six tracks fall into two families: the first four are 'selling goods' (excipients → intermediates → APIs → formulations, with rising margins and barriers), the last two are 'doing deals' (licensing → M&A — the closer to capital, the higher the pay). Suggested path: take your first order in excipients/intermediates, build domain and regulatory depth on the job, then decide whether to upgrade to APIs/formulations or move into deals. A useful analogy: distressed-asset trading is 'find undervalued assets → restructure → sell high'; pharma trade is 'find undervalued suppliers → package for compliance → sell to overseas buyers'; licensing and M&A are 'find undervalued assets → package the value → sell to industrial buyers'. The frame is identical — only the vocabulary changes.
| Track | In one line | Entry barrier | Time to learn | Income (reference) |
|---|---|---|---|---|
| Excipients (pharma-grade) | Volume business, many SKUs, small MOQs — the best first track | Lowest (college/bachelor suffices; deals and resources matter more) | 2–3 months to start; independent in 6 months | Base ¥5–10k/month + commission (often 20–35% of gross margin); roughly ¥150–400k a year once mature (public job-market reference — verify yourself) |
| Intermediates (pharma intermediates) | Mid-high margin, needs some process/impurity knowledge — the volume-scaling track | Medium (process routes, impurity profiles, MSDS) | 3–6 months to start; independent in 6–12 | Base ¥6–12k/month + commission; roughly ¥200–500k a year once mature (public job-market reference — verify yourself) |
| APIs (active ingredients) | High margin, heavy compliance (DMF/CEP/GMP) — the biggest-goods track in both profit and liability | High (DMF/CEP, GMP and the language of registration) | 6–12 months of systematic learning before going solo | Base ¥8–15k/month + commission (often 1% of sales or a gross-margin share); roughly ¥300–800k a year once mature, higher at the top (public job-market reference — verify yourself) |
| Formulations (finished-dose export / international RA) | Highest barrier, highest reward: registrations, shelf life, cold chain — nothing may go wrong | Highest (registrations + shelf-life management + cold chain + market access) | 12 months+ (build your foundation in excipients/APIs first) | Roughly ¥300k–1m a year (international BD/RA tracks; higher at director level — public headhunter reference, verify yourself) |
| Licensing (License-in / License-out BD) | You sell rights, not goods: upfront + milestones + royalties — where legal and deal skills are priced highest | High (most roles want a life-science master's, PhD preferred; legal + deal backgrounds compete asymmetrically) | A 12-month switch plan (2 mo foundation → 2 mo deals → 4 mo practice → 4 mo portfolio) | Entry ¥15–25k×15 (Shanghai associate) → mature ¥600k–1.5m/year → director ¥1–2m+ (2025-26 public headhunter reference — verify yourself) |
| M&A (pharma acquisitions & restructuring) | One deal can make or break: source → value it three ways → diligence → negotiate → close & integrate — the track closest to capital | High (finance/legal/strategy background + nerves; read financial statements before you sit down) | 12 months+ (valuation and diligence are hard skills — start in the simulator) | Base + deal bonus, highly variable: ¥300k–2m+/year depending on platform and level (public industry reference — verify yourself) |
Excipients (pharma-grade)
Volume business, many SKUs, small MOQs — the best first track
Excipients are the 'supporting cast' of drugs: starch, microcrystalline cellulose, magnesium stearate, trehalose... Low unit value but stable, repeat customers; you earn your money on service and professionalism — the ideal sandbox to learn the whole chain.
- · Product knowledge (CP/USP/EP pharmacopoeias) and applications
- · Trade chain & documents (B/L, certificate of origin, packing list, invoice)
- · Outreach & enquiry screening (real buyers vs scam enquiries)
- · Credit-term risk control & customer credit rating
2–3 months to start; independent in 6 months
Base ¥5–10k/month + commission (often 20–35% of gross margin); roughly ¥150–400k a year once mature (public job-market reference — verify yourself)
Newcomers, career switchers, legal/language backgrounds (contracts and compliance are a plus)
Intermediates (pharma intermediates)
Mid-high margin, needs some process/impurity knowledge — the volume-scaling track
Intermediates sit between chemicals and pharma: customers want both low price and controlled impurities. Better margins than excipients, 60–90-day terms, and factory scheduling plus process changes are your daily battlefield.
- · Process & impurity basics (routes, residual solvents, genotoxic impurities)
- · Factory management: schedule follow-up, change control, audit hosting
- · Cost breakdown & tiered quoting
- · Quality-dispute negotiation & claims clauses
3–6 months to start; independent in 6–12
Base ¥6–12k/month + commission; roughly ¥200–500k a year once mature (public job-market reference — verify yourself)
Chemistry/pharmacy backgrounds preferred; people who like processes and plant visits
APIs (active ingredients)
High margin, heavy compliance (DMF/CEP/GMP) — the biggest-goods track in both profit and liability
APIs are the drug substance itself: big deal values, 90–120-day terms, and filing documents are the moat. Whether a DMF/CEP is genuine and what it covers decides whether a multi-million deal can happen — here, compliance skill is bargaining power.
- · The language of filings (structure and review focus of DMF/CEP/ASMF)
- · GMP & quality systems (change control, deviations, OOS)
- · Long-term cash management & credit insurance
- · Technical negotiation (impurities, polymorphs, patent & FTO flags)
6–12 months of systematic learning before going solo
Base ¥8–15k/month + commission (often 1% of sales or a gross-margin share); roughly ¥300–800k a year once mature, higher at the top (public job-market reference — verify yourself)
Pharmacy/chemistry backgrounds; steady people who can carry long payment terms and heavy compliance
Formulations (finished-dose export / international RA)
Highest barrier, highest reward: registrations, shelf life, cold chain — nothing may go wrong
Formulation export is 'selling drugs with registrations in hand': LatAm and MEA markets are hungry, local capacity is thin, and that is the fastest-growing doorway for Chinese finished doses. People who speak Spanish and understand registrations are the scarcest asset in the lane — the ANMAT/INVIMA/COFEPRIS routes are your moat.
- · RA & market access (CTD, country differences)
- · Supply chain & cold chain (shelf life, temperature control, traceability)
- · Pricing & tender/reimbursement environments
- · Local partner management & cross-cultural negotiation
12 months+ (build your foundation in excipients/APIs first)
Roughly ¥300k–1m a year (international BD/RA tracks; higher at director level — public headhunter reference, verify yourself)
Pharmacy + regulatory hybrids; people who want to turn products into businesses, not just move goods
Licensing (License-in / License-out BD)
You sell rights, not goods: upfront + milestones + royalties — where legal and deal skills are priced highest
2025 was a landmark year for China biotech out-licensing (public reports: 150+ deals, well over $100bn total), and assets are sold ever earlier, so the market needs people who can assess risk in R&D language and be trusted by R&D teams. A legal background is not a weakness: your rivals are scientists who cannot structure deals — learn the science language and you compete asymmetrically. Core work: asset scanning → due diligence → term sheet → post-deal management.
- · Science language (follow target/clinical/patent talk and translate it into deal language)
- · Deal documents & clauses (term sheets, licence agreements, risk points)
- · Valuation modelling (rNPV/DCF, hands-on Excel)
- · Due-diligence coordination & virtual data room (VDR) management
- · Cross-cultural negotiation (China–Europe–LatAm time zones and styles)
A 12-month switch plan (2 mo foundation → 2 mo deals → 4 mo practice → 4 mo portfolio)
Entry ¥15–25k×15 (Shanghai associate) → mature ¥600k–1.5m/year → director ¥1–2m+ (2025-26 public headhunter reference — verify yourself)
Law, business or R&D backgrounds all work; people who understand molecules, clinics and patents earn the premium; native Spanish + LatAm connections is a scarce hand
M&A (pharma acquisitions & restructuring)
One deal can make or break: source → value it three ways → diligence → negotiate → close & integrate — the track closest to capital
Pharma M&A scales the game from 'one deal' to 'one factory': intake → pitch book → diligence → four-dimension financial health-check (growth/profitability/efficiency/safety) → three valuation approaches (asset/market/income) → price & negotiate → close & integrate. The industry sits in a restructuring window as innovative drugs start earning; people who can reckon, dare to price, and integrate are scarce long-term.
- · Financial statement analysis & four-dimension health-check
- · Three valuation approaches + comparable-company analysis
- · Diligence organisation (finance, legal, commercial, compliance)
- · Deal structure & negotiation (consideration, earn-outs, liability caps)
- · Integration management (the 100-day plan)
12 months+ (valuation and diligence are hard skills — start in the simulator)
Base + deal bonus, highly variable: ¥300k–2m+/year depending on platform and level (public industry reference — verify yourself)
Finance/legal/strategy backgrounds; distressed-assets, banking or consulting experience maps over naturally (same frame)
3. AI toolkit map: pick by what you want done
The core rule for choosing AI tools: pick by what you want done, not by brand collecting. Master one first (ChatGPT recommended), then compare — paying for ten at once is pure waste. The three tiers below are ready to copy.
Tier 1 · the three must-haves (free tiers are strong enough)
Tier 2 · pick by direction
Tier 3 · the China–West bridge (your differentiated lane)
The rhythm matters more than the tool list. Month 1: master one AI and drill three skills — asking well, verifying answers, knowing when not to trust it. Months 2–3: go deep in one direction (content / development / consulting / automation). Months 4–6: earn with it — ship three real pieces (not demos) to GitHub/Behance/your own site; that is your CV. Remember: do not learn 'tools', learn 'what problems you can solve with them'. Tools change every quarter; 'I can make AI do X for me' never loses value.
4. The generic 12-month roadmap (shared by all six tracks)
Entry: language + products + compliance sprint
- ▸1.5 h a day: jargon table + the four product lines + pharmacopoeia basics
- ▸The six compliance documents + Incoterms + payment-method risk comparison
- ▸Get going on the AI trio (run six small tasks with the four-step delegation formula)
Deliverable: a four-product-line handbook + a 50-entry tri-lingual glossary
Getting started: full chain + prospecting + AI workflows
- ▸Shadow one full deal (enquiry→quote→contract→delivery→cash), one case teardown a week
- ▸Build your product site (catalogue + enquiry form); start LinkedIn outreach
- ▸Send 50 outreach emails a week and log reply rates (ES/EN/ZH templates)
Deliverable: live personal site + 200 outreach emails + reply-rate stats (licensing track: mock term sheet + rNPV model instead)
Independent: real deals / real project diligence
- ▸Close 3 real deals solo (start with a small excipient order) or ride one real project end to end
- ▸Own the core contract clauses (quality disputes, arbitration, liability caps) — the legal background's killer move
- ▸Two industry contacts a week + one deal/case teardown a week (300-word take)
Deliverable: 3 deals + a tri-lingual standard contract template (licensing track: a full due-diligence report)
Deepening: category expert + regional market + monetised network
- ▸Pick your category (peptide/GLP-1 related or ADC suggested) + region (the Spanish-speaking world is your natural edge)
- ▸Build sole-agency relationships (supplier side + customer side); learn LatAm registration requirements
- ▸Tri-lingual CV (ZH/EN/ES) + conference attendance (CPHI and peers)
Deliverable: category-expert positioning + a stable customer base + tri-lingual CV and personal site (that is your interview material)
On income: the bands above combine 2025–26 public job postings and headhunter data (trade tracks run on 'base + commission', uncapped but volatile; deal tracks run on 'base + bonus/royalty share', strongly tied to platform and projects). The numbers set expectations only — verify them yourself; they are not income promises. The common pattern: years 1–2 are an investment period; what really separates people after year 3 is whether they hold a track record of closed deals.